Scarica l'app Stockscreener
59.24
2.87%
-1.75
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Form 4 PTC Therapeutics Inc: Mark Elliott Boulding (EXEC. VP AND CLO) For: 9 October - Investing.com Canada
PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock - MarketBeat
After exercising options at $39.42, PTC Therapeutics (PTCT) CLO Boulding sells 192 shares. - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month LowTime to Sell? - MarketBeat
Ptc Therapeutics stock hits 52-week low at $61.20 - Investing.com
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Form 4 PTC Therapeutics Inc: Glenn JR MD Phd Steele (Director) For: 30 September - Investing.com Nigeria
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Gets Downgrade from Wall Street Zen - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock - MarketBeat
Under a trading plan, Section Six sells 2,500 PTC Therapeutics (PTCT) shares. - Stock Titan
Officer Mark Elliott Boulding proposes selling 192 shares of PTC Therapeutics (Nasdaq: PTCT). - Stock Titan
PTC Therapeutics insider sold 1,638 shares while PTC Therapeutics stock fell 1.36 percent - AD HOC NEWS
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo! Finance Canada
RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating - www.marketscreener.com
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares - MarketBeat
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com - Investing.com India
PTC Therapeutics CLO Mark Boulding sells $132,790 in shares - Investing.com
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
Under a trading plan, PTC Therapeutics (PTCT) CLO sells 1,638 shares, then 435 more. - Stock Titan
Director-linked partnership proposes selling 10,000 PTC Therapeutics (PTCT) shares. - Stock Titan
PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says - marketscreener.com
RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform By Investing.com - Investing.com Canada
Form 144 PTC THERAPEUTICS For: 6 October By Investing.com - Investing.com Nigeria
Cantor raises target for PTC Therapeutics stock to USD 137.00 - AD HOC NEWS
A $27.9K sale of 435 shares is proposed by PTC Therapeutics (PTCT) officer Mark Boulding. - Stock Titan
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Officer Mark Boulding proposes selling 1,638 shares of PTC Therapeutics (PTCT). - stocktitan.net
PTC Therapeutics, Inc. (PTCT) Stock forecasts - uk.finance.yahoo.com
Director Steele Glenn Jr MD PHD Sells 12,000 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock - MarketBeat
After exercising options at $11.23, a director sold 12,000 PTC Therapeutics (PTCT) shares at $65.16. - stocktitan.net
PTCT Stock Price, Quote & Chart - ChartMill
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares. - Stock Titan
Non-controlling/minority interest of PTC Therapeutics, Inc. – HAN:BH3 - TradingView
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo! Finance Canada
PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7%Here's What Happened - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
37 new hires get options to buy PTC shares at $65.96 - Stock Titan
Cantor raises PTC Therapeutics stock price target on Fabry deal By Investing.com - Investing.com Canada
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 - MarketBeat
Cantor Fitzgerald maintains Overweight rating on PTC Therapeutics, $137 price target - TradingView
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com - Investing.com Australia
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026 - TradingView
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy - marketscreener.com
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026. - Stock Titan
1.82%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):